Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Radiotherapy 2Hydroxyurea 2Fluorouracil 2Cisplatin 2Celecoxib 2Etoposide 1Erlotinib Hydrochloride 1Endoscopic Mucosal Resection 1Drug Therapy 1Docetaxel 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paranasal Sinus Neoplasms × Erlotinib Hydrochloride × Clear all
NCT00970502 2017-04-10

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
15 enrolled 16 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡